---
schema_version: "secwatch.filing_event.v1"
accession: "0001708599-25-000110"
form_type: "8-K"
ticker: "SER"
cik: "0001708599"
company_name: "Serina Therapeutics, Inc."
filed_at: "2025-09-15T23:59:59+00:00"
generated_at: "2026-05-17T06:38:58.924807+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Serina Therapeutics enters up to $20M convertible note from director Gregory H. Bailey for clinical study SER-252-1b

## Summary
- Up to $20M drawn in 5 tranches tied to milestones for SER-252-1b registrational study; $5M available by Sept 30, 2025.
- 10% annual interest; conversion at $5.18/share; warrants at $5.44/share for 100% of conversion shares.
- Lender is Dr. Gregory H. Bailey, board member and affiliate of largest shareholder Juvenescence; approved by independent special committee.
- Senior unsecured; prepayable at any time without penalty; mandatory repayment on change of control or liquidity event.
- Maturity 5 years from initial funding; customary events of default with 2% default interest.

## SEC filing metadata
- accession: 0001708599-25-000110
- form_type: 8-K
- ticker: SER
- cik: 0001708599
- company_name: Serina Therapeutics, Inc.
- filed_at: 2025-09-15T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1708599/000170859925000110/0001708599-25-000110-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1708599/000170859925000110/ser-20250909.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001708599-25-000110
- JSON: https://secwatch.observer/filing/0001708599-25-000110.json
- Plain text: https://secwatch.observer/filing/0001708599-25-000110.txt

## Key facts
- Debt Financings
  Serina Therapeutics, Inc. incurred convertible notes of up to $20 million with Gregory H. Bailey, M.D. at annual rate of 10% maturing five years after the initial funding date.
  - Instrument: convertible notes
  - Principal: up to $20 million
  - Counterparty: Gregory H. Bailey, M.D.
  - Rate: annual rate of 10%
  - Maturity: five years after the initial funding date
  - Event: incurrence
  source text: On September 9, 2025, Serina Therapeutics, Inc., a Delaware corporation (the “Company”), entered into an unsecured convertible note (the “Convertible Note”) with Gregory H. Bailey, M.D., a member of the Company’s Board of Directors, making available to the Company an aggregate principal amount of up to $20 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1708599/000170859925000110/0001708599-25-000110-index.htm
- Equity Issuances
  Serina Therapeutics, Inc. issued convertible note to Gregory H. Bailey, M.D. for aggregate principal amount of up to $20 million.
  - Security: convertible note
  - Purchaser: Gregory H. Bailey, M.D.
  - Consideration: aggregate principal amount of up to $20 million
  source text: note (the “Convertible Note”) with Gregory H. Bailey, M.D., a member of the Company’s Board of Directors, making available to the Company an aggregate principal amount of up to $20 million. Under the Convertible Note, borrowings may be drawn in the discretion of the Company in five tranches tied to certain clinical and operational milestones, provided that if at
  evidence_url: https://www.sec.gov/Archives/edgar/data/1708599/000170859925000110/0001708599-25-000110-index.htm
- Equity Issuances
  Serina Therapeutics, Inc. issued 100% of the number of shares issuable upon conversion of the funds extended by the investors on such funding date of warrant to Gregory H. Bailey, M.D. for exercise price equal to $5.44 per share.
  - Security: warrant
  - Shares: 100% of the number of shares issuable upon conversion of the funds extended by the investors on such funding date
  - Purchaser: Gregory H. Bailey, M.D.
  - Consideration: exercise price equal to $5.44 per share
  source text: equal to 100% of the number of shares issuable upon conversion of the funds extended by the investors on such funding date. Such warrants will have an exercise price equal to $5.44 per share. The warrants expire on the earlier of sixty days following the achievement of Milestone 5 or September 30, 2026, unless stockholder approval has not been obtained as
  evidence_url: https://www.sec.gov/Archives/edgar/data/1708599/000170859925000110/0001708599-25-000110-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.